Related Experiment Video
Updated: Jul 5, 2026
05:33
A Model for Epilepsy of Infectious Etiology using Theiler's Murine Encephalomyelitis Virus
Published on: June 23, 2022
Thrombocytopenia during levetiracetam therapy
A Meschede1, U Runge, M Sabolek
1Department of Neurology, EMA University of Greifswald, Sauerbruchstrasse, 17491 Greifswald, Germany.
Epilepsy Research
|April 22, 2008
Summary
Levetiracetam (LEV), an epilepsy medication, was linked to a patient
Area of Science:
- Neurology
- Pharmacology
- Hematology
Background:
- Epilepsy management often involves multiple antiepileptic drugs.
- Thrombocytopenia is a potential adverse effect of certain medications.
- Identifying drug-induced thrombocytopenia is crucial for patient safety.
Purpose of the Study:
- To investigate the potential causal link between levetiracetam (LEV) and thrombocytopenia in a patient with epilepsy.
- To differentiate drug-induced thrombocytopenia from other potential causes.
Main Methods:
- Case report of a 64-year-old patient with epilepsy.
- Analysis of medication history, including valproic acid and levetiracetam.
- Monitoring of platelet counts following drug withdrawal.
Main Results:
- The patient developed thrombocytopenia during levetiracetam treatment.
- Discontinuation of valproic acid did not resolve the thrombocytopenia.
- Cessation of levetiracetam led to rapid and complete resolution of thrombocytopenia.
Conclusions:
- Levetiracetam is a potential cause of drug-induced thrombocytopenia.
- Careful medication review and withdrawal are essential in managing adverse drug reactions.
- This case highlights the importance of considering levetiracetam as a cause of thrombocytopenia in epilepsy patients.
Related Concept Videos
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...